These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29079471)

  • 1. Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.
    Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5252-5257. PubMed ID: 29079471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors.
    Fukuda T; Ueda K; Ishiyama T; Goto R; Muramatsu S; Hashimoto M; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 May; 27(10):2148-2152. PubMed ID: 28377056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of DS79182026: A potent orally active hepcidin production inhibitor.
    Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3716-3722. PubMed ID: 28705644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
    Fukuda T; Ishiyama T; Katagiri T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Baba D; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3333-3337. PubMed ID: 30217414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
    Cheruvallath ZS; Gwaltney SL; Sabat M; Tang M; Wang H; Jennings A; Hosfield D; Lee B; Wu Y; Halkowycz P; Grimshaw CE
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2678-2682. PubMed ID: 28512030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
    Zhang X; Song F; Kuo GH; Xiang A; Gibbs AC; Abad MC; Sun W; Kuo LC; Sui Z
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4762-7. PubMed ID: 21767952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target identification of hepcidin production inhibitors by a combination of chemical proteomics and radioactive compound binding assay.
    Sasaki M; Ueda K; Fukuda T; Tanaka N; Shimizu H; Kubota K
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2878-2884. PubMed ID: 30139518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
    Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
    Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel series of indazole-/indole-based glucagon receptor antagonists.
    Lin S; Zhang F; Jiang G; Qureshi SA; Yang X; Chicchi GG; Tota L; Bansal A; Brady E; Trujillo M; Salituro G; Miller C; Tata JR; Zhang BB; Parmee ER
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4143-7. PubMed ID: 26303893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists.
    Lamotte Y; Faucher N; Sançon J; Pineau O; Sautet S; Fouchet MH; Beneton V; Tousaint JJ; Saintillan Y; Ancellin N; Nicodeme E; Grillot D; Martres P
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1098-103. PubMed ID: 24462665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pyrazole and indazole derivatives: synthesis and evaluation of their anti-proliferative and anti-angiogenic activities.
    Tzanetou E; Liekens S; Kasiotis KM; Fokialakis N; Haroutounian SA
    Arch Pharm (Weinheim); 2012 Oct; 345(10):804-11. PubMed ID: 22707414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.
    McBride C; Cheruvallath Z; Komandla M; Tang M; Farrell P; Lawson JD; Vanderpool D; Wu Y; Dougan DR; Plonowski A; Holub C; Larson C
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2779-2783. PubMed ID: 27136719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformationally restricted novel pyrazole derivatives: synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors.
    Reddy TS; Kumar KS; Meda CL; Kandale A; Rambabu D; Krishna GR; Hariprasad C; Rao VV; Venkataiah S; Reddy CM; Naidu A; Dubey PK; Parsa KV; Pal M
    Bioorg Med Chem Lett; 2012 May; 22(9):3248-55. PubMed ID: 22464134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of indazoles as inhibitors of Tpl2 kinase.
    Hu Y; Cole D; Denny RA; Anderson DR; Ipek M; Ni Y; Wang X; Thaisrivongs S; Chamberlain T; Hall JP; Liu J; Luong M; Lin LL; Telliez JB; Gopalsamy A
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4758-61. PubMed ID: 21742493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury.
    Liu Z; Chen L; Yu P; Zhang Y; Fang B; Wu C; Luo W; Chen X; Li C; Liang G
    J Med Chem; 2019 Jun; 62(11):5453-5469. PubMed ID: 30998353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentosan polysulfate to control hepcidin expression in vitro and in vivo.
    Asperti M; Denardo A; Gryzik M; Castagna A; Girelli D; Naggi A; Arosio P; Poli M
    Biochem Pharmacol; 2020 May; 175():113867. PubMed ID: 32088260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of IL-22 contribution to hepcidin induction and hypoferremia during the response to LPS in vivo.
    Wallace DF; Subramaniam VN
    Int Immunol; 2015 Jun; 27(6):281-7. PubMed ID: 25568302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
    Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.